.png)
.png){kind=logo}
Sanofi is sponsoring a competition to award two Golden Tickets: one at BioLabs Hôtel-Dieu and one at BioLabs Heidelberg. Each Golden Ticket provides one year of fully paid individual office and bench space, plus membership at a fully equipped laboratory designed to accelerate early-stage startups working on Small Molecule Modulators of RNA Splicing or Novel Therapeutics & Diagnostics in Endometriosis.
Additional eligibility requirements are listed below.
Application Process
The official application process can be found below. Please read and verify your availability before submitting your application.
Golden Ticket Benefits
Eligibility Snapshot
We are seeking innovative companies working in one or both of the following areas:
Call for Projects — Small Molecule Modulators of RNA Splicing
Cell-based screening and tool validation — Cellular assays enabling the identification and characterization of small molecules interacting with RNA, including tool compound validation in disease-relevant cellular contexts. Fit-for-purpose assay development for RNA–small molecule interactions is a priority.
RNA–small molecule binding and structural biology — Biophysical interaction profiling platforms leveraging NMR, X-ray crystallography, or CryoEM to characterize RNA–small molecule binding. Robust, reproducible methodologies with translational relevance are strongly preferred.
In silico methodologies and AI-driven approaches — Computational tools and AI-based methods specifically designed for RNA structure prediction and RNA–small molecule interaction modeling, including hit identification and lead optimization support.
We will also consider RNA-focused chemical libraries building — dedicated compound collections purpose-built for RNA targeting, with demonstrated selectivity and drug-like properties.
REM: Even if small molecules is the modality to be developed, oligonucleotides are also of interest especially as tool molecules to drive the MoA validation.
Out of scope: Protein-targeted approaches, gene/cell therapies, antisense modalities, target discovery platforms without small molecule applicability, and programs lacking a credible path to oral or systemic drug candidates.
Call for Projects — Novel Therapeutics & Diagnostics in Endometriosis
Novel therapeutic programs with compelling preclinical proof-of-concept and a credible clinical development path — prioritizing non-hormonal or hormone-sparing approaches targeting pain, lesion burden, inflammation, and/or fibrosis. Patient stratification capabilities will strengthen development potential.
Validated disease-relevant model systems that meaningfully mimic human endometriosis biology and are fit for drug screening and profiling — including patient-derived in vitro/ex vivo models, translational in vivo models, and screening-ready assays. This is an area of particular need.
We also consider diagnostic concepts with credible clinical validation pathways, particularly minimally invasive assays that reduce time-to-diagnosis.
Out of scope: Cell/gene therapies, target discovery platforms, engineering-first solutions, manufacturing platforms, and programs without plausible human translation.
The Application Process
01
Submit the online application by June 5th, 2026
02
A subset of applications will be identified as finalist by the contest judges by
June 22nd, 2026
03
Finalist teams will present their company & scientific concept at a virtual event on
July 10th,2026
04
One award will be granted for Paris and one award for Heidelberg.
Good luck!
Contact Us
